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Inflamación.
Allergic rhinitis (AR) is characterized by IgE-mediated 
reactivity that leads to inflammation of the nasal mucosa by a 
typical cellular pattern consisting of eosinophils, lymphocytes, 
and mast cells.
Several allergens can cause AR, although pollens are 
the most common source. Each type of pollen has a specific 
pollination season and biological properties that affect 
proinflammatory activity [1]. Allergic inflammation is closely 
related to pollen exposure [2].
The weed Parietaria officinalis is found throughout the 
Mediterranean area; it is a common source of sensitization, 
and its pollination period is long [3]. In southern Italy, many 
physicians consider Parietaria pollen to be a perennial allergen.
The aim of this study was to confirm the relationship 
between exposure to pollen and inflammatory events in a 
group of AR patients allergic only to Parietaria by assessing 
inflammatory cells monthly over a 1-year period. Our study 
population comprised 20 patients (11 males and 9 females, 
median age 35 years) with AR due to Parietaria pollen who 
were seen consecutively at the Rhinoallergology Outpatient 
Clinic of the Department of Otorhinolaryngology of the 
University of Bari, Italy in 2011. 
The inclusion criteria were a confirmed diagnosis of AR 
according to the Allergic Rhinitis and Its Impact on Asthma 
guidelines [6] and monosensitization to Parietaria pollen. 
Nasal cytology was performed monthly during the study. The 
pollen count for the whole of 2011 was recorded.
Patients underwent the following procedures:
Skin prick test: Allergy was assessed by performing a skin 
prick test with a panel of the most common aeroallergens 
according to the recommendations of the European Academy 
of Allergy and Clinical Immunology [4]. The patient was 
considered to have Parietaria-induced AR if the nasal 
symptoms were consistent with sensitization.
Nasal cytology: The procedure was performed by scraping 
the middle part of the inferior turbinate with a Rhino-Probe 
(Arlington Scientific). The sample was smeared on a slide, 
fixed by air-drying, and colored using May-Grünwald 
Giemsa staining. Coloration quality and cell distribution were 
examined using microscopy (original magnification, x400); 
cell types were identified, and intracellular components were 
studied at x1000 in immersion. The mean number per 50 fields 
was calculated and reported as previously described [5].
Parietaria pollen count: We recorded 52 mean weekly 
Parietaria pollen concentration values and peaks (grains/m3 of air) 
in Bari, Italy between January 1, 2011 and December 31, 2011.
The Parietaria pollen season started on the 98th day of 
the year and ended on the 289th day. We observed 2 peaks: 
the first was between April and May, and the second between 
late August and early September. The Figure shows the trend 






















































Inflammatory cells appeared from April to October; the nasal 
infiltrate was present throughout the pollen season. Again, we 
observed 2 peaks: the first, and more intense, occurred during 
the first 3 months (April-June); the second was in September. 
Eosinophils were the most frequent inflammatory cells 
detected in nasal mucosa. Mast cells and lymphocytes were 
less common. The trend can be seen in the Figure. 
Nasal inflammation is indispensable for the development 
of symptoms in patients with AR. Severity of inflammation is 
typically dependent on the pollen species [1], and it has been 
reported that minimal persistent inflammation may also occur 
in patients with pollen allergy [2]. The most common allergic 
disorder, pollen allergy (also known as hay fever) affects up to 25% 
of the general population [6]. Parietaria allergy is very frequent in 
the Mediterranean area [7], and many physicians believe that the 
Parietaria pollen season may last the whole year, thus potentially 
affecting clinical practice (especially when programming allergen 
immunotherapy). In fact, most prescriptions for Parietaria-allergic 
patients involve perennial treatment. 
Figure. Parietaria pollen count and inflammatory cells (assessed monthly) 
during 2011.
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In the present study, we addressed this relevant issue by 
monitoring inflammation over a whole year and by measuring 
the pollen count. We analyzed 3 types of inflammatory cells, 
namely, eosinophils, lymphocytes, and mast cells, since these 
are the most commonly involved in allergic inflammation.
Eosinophils are the main effector cells in allergic 
inflammation; consequently, if no eosinophils are identified 
in nasal cytology samples, allergic inflammation can be ruled 
out. Moreover, the degree of eosinophilic infiltration is closely 
associated with symptom severity [1].
Lymphocytes play a key role in orchestrating allergic 
inflammation, since allergy is characterized by polarization 
of TH2 cells. In fact, production of IgE and eosinophilic 
inflammation are controlled by TH2-dependent cytokines such 
as IL-4 and IL-13.
Mast cells are involved in the early phase reaction; when 
activated by allergen exposure, they release the mediators 
responsible for the onset of symptoms.
The first relevant finding of our study was that the pollen 
season lasted for about 6 months during 2011. While this 
is a long season, it is not perennial. Of note, this trend was 
also observed in other years (data not shown). In addition, 
pollen was identified in waves, with peaks and absences. The 
second relevant finding was that inflammation was observed 
throughout the season and involved mainly eosinophilic 
infiltrate. The trend for allergic inflammation accurately 
mirrors that of the pollen season, with 2 main peaks: spring 
and September.
Our findings are important for clinical practice. Even though 
Parietaria allergy lasts 6 months, inflammation lasts only 4 
months. Knowledge of the seasonality of nasal inflammation 
will enable us to explore innovative administration schedules 
for allergen immunotherapy in the near future. Indeed, further 
studies should be conducted to investigate whether patients 
with Parietaria allergy should undergo a single pre–coseasonal 
course, as is the case in other pollen species [8].
The main limitation of our study is its lack of clinical data. 
Therefore, further assessment of symptoms is mandatory in 
order to confirm the clinical value of this research.
In conclusion, our findings show that the Parietaria pollen 
season in Bari lasts about 6 months and that the duration of 
allergic inflammation is closely associated with the duration 
of the pollen season.
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Food protein–induced enterocolitis syndrome (FPIES) 
is an uncommon and potentially severe non–IgE-mediated 
gastrointestinal food allergy characterized by delayed profuse 
vomiting and diarrhea that can progress to dehydration and 
shock [1]. The pathophysiology, prevalence, natural history, 
and diagnosis of FPIES remain poorly understood, and the few 
data available in the literature comprise single case reports 
or small case series [2-6]. One recently published large case 
series did not report patient outcome [7]. 
We performed a retrospective study covering a 12-year 
period (1999-2011) by screening the hospital medical record 
database for diagnosis and outcome of FPIES. Sixteen 
children were referred to our outpatient clinic for a food 
allergy work-up. The symptoms observed following exposure 
to the culprit food were consistent with FPIES [1], namely, 
repeated and delayed (1-3 hours) vomiting and/or diarrhea 
with (out) lethargy and no other explanation for the symptoms. 
The food allergy workup was performed according to the 
recommendations of the Spanish Society of Allergy and 
Clinical Immunology [8]. 
The study population comprised 10 boys and 6 girls aged 
between 11 months and 12 years (mean [SD], 50.6 [37.4] 
months) at the time of the study. All patients had symptoms 
the first time they ingested the offending food. Vomiting was 
recorded in 16 patients (100%), diarrhea in 9 (56%), lethargy 
in 4 (25%), irritability in 3 (19%), pallor in 3 (19%), and 
dehydration in 1 (6%) (Table). In all cases, the time between 
ingestion and onset of acute symptoms was over 2 hours. 
Before diagnosis, 14 patients (87.5%) had had more than 1 
reaction (range, 1-4), and 5 (31%) had required emergency 
care because of dehydration and/or lethargy. Five had negative 
screening results for celiac disease, and 2 underwent intestinal 
biopsy. Fifteen (93.7%) children reacted to only 1 food protein. 
Table. Food Protein–Induced Enterocolitis Syndrome: Clinical and Developmental Characteristics of the Study Population
Patient No./   Age at Culprit Food/ Diagnostic Symptoms  Age at Evaluation, mo 
Age at Time Diagnosis,  No. of Reactions  by CH/OFC 
of Study, mo mo Prior to Diagnosis  Positive OFC  Negative OFC
1/11 6 Milk/2 V, D, L/NP a  a
2/17 3 Milk/1 V, I/NP 13 
3/48 14 Milk/2 V, D, L/V   24
4/29 6 Milk/2 V, D/V 12   24
5/40 1 Milk/2 V, D/V, L 12, 22  36
6/43 2 Milk/3 V, D, I/D, L 13  24
7/39 1 Milk/2 V, D/NP 14, 22  36
8/24 6 Soy milk/1 V, D/V   14
9/60 30 Fish/3 V/NP 36 
10/108 Legume: 12   Legume/1   V/V, P  Legume: 28, 48  Legume: 72 
 Fish: 20 Fish/3  Fish: 36, 84  
11/96 13 Fish/2 V, D/V, P, Dh 36, 60, 72 
12/144 7 Fish/3 V, L, Dh/NP 16, 24, 48, 60, 108  144
13/38 8 Fish/2 V, L/NP 18  24
14/30 6 Rice/2 V, P/D 12  24
15/72 7 Wheat/2 V, D, P/V 22, 48 
16/11 7 Chicken/2 V, P/NP 11b  a
Abbreviations: CH, clinical history; D, diarrhea; Dh, dehydration; I, irritability; L, lethargy; NP, not performed; OFC, oral food 
challenge; P, pallor; V, vomiting. 
aFollow-up OFC not performed. 
bAccidental exposure.
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Cow’s milk was the trigger in 7 children (44%), with a mean 
age at diagnosis of 4.7 (4.6) months (range, 1-14 months); fish 
(sole, whiff, hake) was the main trigger in 5 (31%) patients, 
with a mean age at diagnosis of 15.6 (9.6) months (range, 7-30 
months). Soymilk, rice, wheat, legume (lentil), and chicken 
were the trigger in 5 patients (Table).
Skin prick test and serum specific IgE results were negative 
in all cases except patient 6, whose serum specific IgE was 
0.56 kUA/L for cow’s milk and <0.35 kUA/L for cow’s milk 
protein at diagnosis; he tolerated milk at 24 months. He 
had never experienced an immediate reaction to milk, even 
during a positive oral food challenge (OFC) at 13 months. 
Seven patients were diagnosed with FPIES based on clinical 
symptoms and 9 based on OFC. The median latency period 
between food intake and reaction was 2 hours (range, 50 
minutes-4 hours), and symptoms were similar to those recorded 
at the first clinical visit. 
Patients were followed at our clinic every 6-12 months 
(mean 8.2 [2.4] months) until tolerance was achieved. OFC 
was performed to confirm tolerance after the causal protein 
was removed from the diet. The mean time between the 
last FPIES reaction (clinical symptoms or diagnostic OFC) 
and the next OFC was 10.17 (2.32) months for cow’s milk 
and 13.67 (7.40) months for solid foods. The mean age of 
resolution for all tolerated foods was 42.2 (39.13) months 
(range, 14-144 months). Five patients tolerated cow’s milk 
with a mean age of 28 (6.57) months (range, 24-36 months), 
and 2 tolerated fish with a mean age of 84 (84.85) months 
(range, 24-144 months). The mean age at resolution for 
solid foods (fish, rice, legume) was 66.25 (56.95) months 
(range, 24-144 months); for milk (cow’s and soy) the mean 
age at resolution was 26.33 (8.43) months (range, 14-36 
months) (P=.017). 
At the time of the study, 7 patients did not tolerate the 
trigger (mean age, 30.5 [25.25] months). Five patients had a 
positive OFC result: 1 patient to cow’s milk (age 13 months), 
1 patient to wheat (twice, at age 22 months and 4 years), and 
3 patients to fish (age 3, 6, and 7 years). Patient 11 was treated 
in the intensive care unit for severe dehydration, hypotension, 
and loss of consciousness after the last fish OFC. Two patients 
did not undergo food challenge because they were too young 
(patients 1 and 16).
FPIES is often misdiagnosed and thus carries a risk of 
repeated reactions and additional and often unnecessary 
procedures. FPIES is a potentially severe illness, and the 
differential diagnosis must distinguish between IgE-mediated 
allergy, anaphylaxis, and sepsis [9,10]. There are no laboratory 
tests to identify which foods cause FPIES. All those patients 
who did not undergo the diagnostic OFC had a positive follow-
up OFC, demonstrating that the clinical history is a good tool 
for early diagnosis.
Although the symptoms that appear during an OFC are 
usually mild, severe reactions may occur. Therefore, physician-
supervised OFC should be used to monitor the development of 
tolerance; however, in our opinion, OFC is not necessary for 
diagnosis in patients with clear symptoms of FPIES.
 The most frequent cause of FPIES in our series was 
cow’s milk. This finding is consistent with the results obtained 
from other groups, including the largest series to date [7] and 
a Mediterranean population [6]. For solid foods, the most 
frequent eliciting food was fish, as in previous reports from 
Italy [6] and Spain [3]; other studies reported cereals as the 
most frequent solid food cause of FPIES [4,5,10]. The higher 
number of cases of FPIES caused by fish in our population 
can be explained by nutritional habits. Therefore, fish should 
always be considered a potential risk for FPIES, especially in 
Mediterranean populations. 
According to previously published findings, the age at 
which patients in our population present symptoms and the 
age at which they achieved tolerance for cow’s milk were 
significantly lower than the age at which they tolerated solid 
foods [6]. This may be because cow’s milk is introduced earlier 
in the diet, but also because FPIES caused by solid food lasts 
longer. Therefore, we suggest performing follow-up OFC 
with cow’s milk at 24 months or older and with solid food, 
specifically fish, even later, since the chances of tolerance 
before are low. 
FPIES is a potentially severe disease. The clinical history 
is the main tool for early diagnosis, but clinician-supervised 
OFC is necessary for the follow-up of food tolerance. Cow’s 
milk is the most common cause of FPIES in our population, 
followed by fish, which is tolerated later. This is the first 
published series of cases of FPIES caused by different foods 
in a Spanish population.
Funding
The authors declare that no funding was received for the 
present study.
Conflicts of Interest
The authors declare that they have no conflicts of interest.
References
1. Sicherer SH. Food protein-induced enterocolitis syndrome: 
case presentations and management lessons. J Allergy Clin 
Immunol. 2005;115:149-56. 
2. Katz Y, Goldberg MR, Rajuan N, Cohen A, Leshno M. The 
prevalence and natural course of food protein–induced 
enterocolitis syndrome to cow’s milk: a large-scale, 
prospective population-based study. J Allergy Clin Immunol. 
2011;127:647-53.
3. Zapatero Remón L, Alonso Lebrero E, Martín Fernández E, 
Martínez Molero MI. Food-protein-induced enterocolitis syndrome 
caused by fish. Allergol Immunopathol. 2005;33:312-6.
4. Mehr S, Kakakios A, Frith K, Kemp AS. Food protein-induced 
enterocolitis syndrome: 16-year experience. Pediatrics. 
2009;123;e459.
5. Nowak-Wegrzyn A, Sampson HA, Wood RA, Scott SH. Food 
protein-induced enterocolitis syndrome caused by solid food 
proteins. Pediatrics. 2003;111:829.
6. Sopo SM, Giorgio V, Dello Iacono I, Novembre E, Mori F, 
Onesimo R. A multicentre retrospective study of 66 Italian 
children with food protein-induced enterocolitis syndrome: 
different management for different phenotypes. Clin Exp 
Allergy. 2012;42:1257-65. 
Practitioner's Corner
J Investig Allergol Clin Immunol 2014; Vol. 24(5): 352-370© 2014 Esmon Publicidad
356
7. Ruffner MA, Ruymann S, Cianferoni A, Brown-Whitehorn T. 
Food protein-induced enterocolitis syndrome: insights from 
review of a large referral population. J Allergy Clin Immunol 
Pract. 2013;1:343-9. 
8. Ibáñez MD, Alonso E, Blanco C, Cisteró A, Cuesta J, Fernández-
Rivas M, Florido JF, García B, Laffond E, Matín F, Nieto A, Rico 
A, Rodríguez J. Comité de Alergia a alimentos. Metodología 
diagnóstica en alergia a alimentos. Alergol Inmunol Clin. 
1999;14:50-62. 
9. Coates RW, Weaver KR, Lloyd R, Ceccacci N, Greenberg MR. 
Food protein-induced enterocolitis syndrome as a cause for 
infant hypotension. West J Emerg Med. 2011;12:512-4.
10. Järvinen KM, Nowak-Węgrzyn A. Food Protein-Induced 
Enterocolitis Syndrome (FPIES): Current Management 
Strategies and Review of the Literature. J Allergy Clin Immunol 
Pract. 2013;1:317-22
  Manuscript received July 15, 2013; accepted for publication July 
18, 2013. 
María Dolores Paloma Ibáñez Sandín
Servicio de Alergología
Hospital Infantil Universitario Niño Jesús
Avda. Menéndez Pelayo, 65
28009 Madrid, Spain
E-mail: mibanezs@salud.madrid.org
Chronic Urticaria in a Celiac Patient: Role of Food 
Allergy
E Heffler,1,2 E Bruna,1 G Rolla2
1Allergy Outpatients’ Clinic, ASL-TO3, Ospedale Civile “Edoardo 
Agnelli,” Pinerolo (TO), Italy
2Allergy and Clinical Immunology, Department of Medical 
Sciences, University of Torino, Torino, Italy
Key words: Chronic urticaria. Food allergy. Buckwheat. Celiac disease. 
Palabras clave: Urticaria crónica. Alergia alimentaria. Trigo sarraceno. 
Enfermedad celíaca.
We present the case of a 37-year-old woman who was 
referred to our allergy outpatient clinic with an 18-month 
history of chronic urticaria. She was not taking medication, 
and her clinical history revealed celiac disease diagnosed about 
3 years previously. The disease was very well controlled with 
a strict gluten-free diet, in which the patient consumed foods 
containing rice, soybean, and buckwheat flours.
No apparent correlation was found between ingestion of 
specific foods or drugs and the appearance of hives, which 
were present almost every day. Urticaria was controlled with 
levocetirizine dihydrochloride 5 mg/d but reappeared when 
she stopped taking the medication.
Physical examination was unremarkable except for a few 
hives on her back, abdomen, and lower limbs.
We performed a skin prick test with a standard panel of 
6 common inhalant and 13 food allergens (including rice 
and soybean) and prick-by-prick test with buckwheat flour 
(as described elsewhere [1]). The results of the skin prick 
test were positive for house dust mites (Dermatophagoides 
pteronyssinus and Dermatophagoides farinae) and grass 
pollen; the results of the prick-by-prick test were positive for 
buckwheat flour (12-mm [histamine control, 7 mm]).
The patient was advised to avoid buckwheat-containing 
foods for at least 2 weeks and to try to reintroduce them into her 
diet after 2 weeks. She was also advised to take levocetirizine 
dihydrochloride 5 mg/d if needed.
We also assessed specific IgE to buckwheat (ImmunoCAP, 
Phadia), complete blood count, determination of C3 and C4 
levels, erythrocyte sedimentation rate, C-reactive protein levels, 
and antibody titers (antithyroid, antinuclear, and anti-DNA).
One month after the allergy workup the patient attended 
our outpatient clinic for a checkup and reported that her 
urticaria disappeared when she avoided buckwheat-containing 
foods and reappeared when she tried to reintroduce them into 
her diet. She now avoids buckwheat, her urticaria has resolved 
completely, and she no longer needs to take levocetirizine 
dihydrochloride.
Specific IgE testing for buckwheat was positive (68 kUA/L). 
The results of all other determinations were normal.
Chronic urticaria is a complex disease in which food allergy 
very rarely has a causative role. IgE-mediated food allergy 
is far more likely to present with acute urticaria as part of a 
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generalized reaction. The pathogenesis of chronic urticaria is 
still not completely clear [2], although the disease has been 
associated with comorbid conditions (eg, systemic autoimmune 
disorders [including celiac disease], thyroid disorders, and 
chronic infections) and aggravating factors (physical stimuli 
[eg, heat, pressure, and dermographism], anti-inflammatory 
medication [eg, nonsteroidal anti-inflammatory drugs], and 
other drugs [eg, angiotensin-converting enzyme inhibitors]) [3].
In the present case, food allergy to buckwheat was the only 
trigger of urticaria that had a chronic course. The patient was 
eating buckwheat-containing foods almost every day, since 
buckwheat is a common supplement to cereal grains consumed 
by celiac patients. No comorbid conditions other than celiac 
disease or aggravating factors were found.
Buckwheat allergy is considered rare in Europe, although 
recent reports show that its prevalence is increasing, mostly 
because it is more often used as an ingredient in foods that are 
not supposed to contain it, thus making it a hidden allergen [1,4]. 
In a previous report, we identified 3 distinct patterns of 
clinical and laboratory characteristics of buckwheat-allergic 
patients, suggesting that specific allergens could be more 
frequently associated with clinical manifestations of varying 
severity [4]. The characteristics were a 16-kDa band in 
patients with predominantly gastrointestinal symptoms who 
were cosensitized to grass and wheat flour, a 25-kDa band in 
patients with predominantly cutaneous symptoms and a low 
frequency of cosensitization, and a 40-kDa band in patients 
with anaphylaxis and a low frequency of cosensitization. 
Unfortunately, since we did not perform immunoblotting, 
we were unable to assign this patient to one of these groups.
In conclusion, we report a case of chronic urticaria in a 
patient with celiac disease and allergy to buckwheat (one of 
the permitted flours for celiac patients). Our findings show that, 
even if IgE-mediated food allergy is a rare occurrence, it should 
be investigated in patients with chronic urticaria, particularly 
in groups with specific dietary restrictions, such as patients 
with celiac disease. Two recent reports showed that other 
food allergens (Anisakis simplex [5] and peach lipid transfer 
protein [6]) may cause chronic urticaria in specific cases.
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Specific oral immunotherapy (SOIT) has been attracting 
attention as a potentially novel approach in patients with 
food allergy [1]. SOIT involves oral administration of the 
offending food, starting at very low doses and increasing 
gradually until the patient can tolerate the usual daily 
intake. However, since the safety of SOIT has not been well 
established, this approach is not currently recommended for 
use in clinical practice [2]. Additionally, uncertainty about 
whether SOIT induces complete tolerance or only transient 
desensitization [1,3] means that patients must be closely 
monitored after desensitization. We report the case of a 
patient with wheat allergy who experienced 2 episodes of 
wheat-dependent exercise-induced anaphylaxis (WDEIA) 
after apparently successful desensitization.
The patient was a 7-year-old boy who experienced his 
first anaphylactic reaction 30 minutes after ingesting food 
containing wheat when he was 6 months old. The results of 
an ImmunoCAP test (Phadia) performed at 7 months of age 
were positive to wheat (54.1 kUA/L). This value increased 
to 88.9 kUA/L at 11 months of age. Although the results for 
egg white and soybean were also positive (9.43 kUA/L and 
7.56 kUA/L, respectively), the patient tolerated both foods. 
He was diagnosed as having wheat allergy, and his parents 
were advised to eliminate wheat from his diet. Subsequent 
repeated ImmunoCAP testing showed that levels of IgE to 
wheat had gradually decreased. The ImmunoCAP results 
for wheat and w-5-gliadin at 7 years of age were 0.83 kUA/L 
and negative, respectively. However, the patient experienced 
3 anaphylactic reactions following inadvertent ingestion 
of wheat. Symptoms included massive hives, angioedema, 
cough, wheeze, and breathing difficulty. The patient was 
referred to our clinic for wheat-specific oral immunotherapy. 
After admission, he was challenged with 0.3 g of noodles 
made from wheat flour, and, within 30 minutes, multiple 
hives appeared on his body, confirming that he was still 
allergic to wheat. Oral immunotherapy was then started at 
an initial dose of 0.1 g of noodles twice a day, which was 
increased 1.5-fold twice a week, and then 1.1-fold at each 
ingestion. The objective was to enable the patient to safely 
ingest 100 g of noodles. During the procedure, he developed 
localized hives at 2.7 g and 22 g, although the symptoms 
were not severe. During his stay in hospital (4 months), he 
did not perform strenuous exercise, but tolerated activities 
of daily living. At the end of his stay, he was able to eat 
100 g of noodles. Further challenges with portions of other 
wheat-containing foods, such as bread, macaroni au gratin, 
and wheat-containing curry, elicited no symptoms. He was 
discharged and followed up in the outpatient clinic, with 
regular intake of wheat-containing products at home. Since 
he experienced no reactions during the following month, 
wheat was introduced to his school lunch menu.
Two months later, he developed massive hives, cough, 
wheezing, and breathing difficulty while playing soccer 
after eating wheat-containing foods at school. He was taken 
immediately to the emergency room, where he received 
intramuscular adrenaline and was kept under observation 
until the following day. Given the suspicion of WDEIA, 
he was advised not to exercise within 2 hours after eating 
wheat-containing foods and not to eat wheat-containing 
foods if he planned to exercise within 2 hours of eating. 
However, he experienced a similar anaphylactic reaction 
while running around at home after eating wheat-containing 
bread for breakfast. He was treated with an adrenaline 
autoinjector (Epipen) by his mother and taken to hospital. 
Strict avoidance of exercise after wheat-containing foods was 
again recommended, and he has since had no further episodes 
of anaphylaxis. Exercise without prior ingestion of wheat did 
not provoke symptoms. An exercise challenge after an intake 
of wheat was not performed because informed consent was 
not obtained.
The patient experienced 2 episodes of WDEIA, even 
though his ImmunoCAP values for wheat decreased 
and he had completed the desensitization protocol. The 
pathophysiology of WDEIA is not well understood; however, 
several working hypotheses have been put forward, including 
increased tissue activity, epitope recognition, altered 
gastrointestinal permeability, and autonomic aberrations [4]. 
Our findings suggest that, while SOIT can suppress allergic 
reaction induced by simple ingestion of wheat, it does not 
alter the additional mechanisms that induce WDEIA. Wheat 
and shellfish are the 2 main causes of food-dependent, 
exercise-induced anaphylaxis (FDEIA) [5], although a 
myriad of other food allergens have been associated with 
this condition [4]. A similar case of WDEIA during SOIT 
has been reported [6]. Consequently, patients with wheat 
allergy should be closely monitored for WDEIA, even 
after apparently successful desensitization with SOIT. Our 
experience indicates that a decreased ImmunoCAP value for 
wheat does not guarantee safety. While the ImmunoCAP level 
of w-5-gliadin has proven useful for diagnosing WDEIA in 
adults, this is not necessarily so in children [7], as shown in 
the case we report. FDEIA has been reported after successful 
desensitization in a patient with milk allergy [8]. Although 
SOIT is a promising option for treatment of food allergy in 
the future, many unanswered questions remain, particularly 
concerning the stability of the effect. Thus, the possibility 
of FDEIA should be borne in mind, and careful follow-up is 
required after apparently successful desensitization.
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Boxwood (Buxus sempervirens) is a shrub that grows 
throughout Europe [1]. Its hardness makes it extremely useful, 
not just for ornamental purposes, but also for the manufacture 
of items such as agricultural implements, kitchen utensils, 
and even musical instruments (eg, Galician bagpipes). Wood 
allergy is relatively common, especially among people who 
work in the wood industry, and is the subject of several 
publications [2-4]. Boxwood allergy, however, has seldom 
been reported [5], and, to our knowledge, there are no reports 
of IgE-mediated allergy triggered by exposure to this wood.
We present a case of allergic reaction to boxwood in 
which sensitization was demonstrated by skin testing and 
IgE-immunodetection.
The patient was a 52-year-old man with rhinoconjunctivitis 
and persistent mild asthma (sensitization to house dust mites) 
who was taking symptomatic treatment (inhaled long-acting 
bronchodilators and corticosteroids). He smoked 20 cigarettes 
a day between the ages of 20 and 49 years, and had been a 
moderate alcohol drinker since age 20. For the last 2 years, he 
had experienced immediate and late reactions that manifested 
as rhinoconjunctivitis and cough when working with boxwood. 
He reported no urticaria or dermatitis on contact with 
boxwood. The symptoms began after he inhaled microparticles 
produced by a lathe he had bought 2 years previously for his 
woodwork hobby.
He associated the onset of symptoms with boxwood, 
because they did not occur when he worked with other woods 
(ie, beech, apple, cherry, birch, oak, walnut, and chestnut). 
He stopped working with boxwood for a few months and 
experienced no respiratory symptoms in his workshop. 
Skin prick tests with a series of airborne allergens 
commonly found in our setting (ALK-Abelló SA) were 
positive for dust mites. Skin tests with a series of wood extracts 
(cherry, sapele, pine, chestnut, beech, iroko, medium-density 
fiberboard, bubinga, obeche, southern yellow pine, and 
okoume; Diater Laboratories SA) proved negative, except 
for boxwood extract (wheal size 10×10 mm). This extract 
was prepared at 10% (wt/vol) in phosphate-buffered saline 
by magnetic stirring for 90 minutes at 5ºC. After filtration 
through a 0.22-µm membrane, the extract was freeze-dried 
before being reconstituted with phosphate buffer in one-fifth 
of the original volume. For the skin test, the extract was mixed 
with glycerol in equal parts.
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The boxwood extract was tested in 5 atopic and 5 nonatopic 
patients, yielding negative results in all cases. The patient 
refused to undergo challenge tests.
The results of serum IgE determination (ImmunoCAP, 
Thermo Fisher Scientific) were as follows: total, 1101 kUA/L; 
Dermatophagoides pteronyssinus, 31.8 kUA/L; Lepidoglyphus 
destructor, 2.2 kUA/L; birch pollen, 1.09 kUA/L; latex, 
1.57 kUA/L; MUXF3, 1.04 kUA/L; rBet v1, rBet v4, and 
rPru p 3, negative; recombinant latex allergens (Hev b 1, 3, 
5, 6, 8, 9, and 11), negative.
The Figure shows the result of IgE-immunodetection 
with the boxwood extract, which was separated by molecular 
weight into its protein components using SDS-PAGE under 
nonreducing conditions. The proteins were then transferred to 
nitrocellulose membranes, which were sequentially incubated 
with the patient’s serum, a monoclonal antihuman IgE antibody 
(HE-2, ALK-Abelló SA) and a peroxidase-conjugated 
antimouse IgG antibody (RAM-HRP, DAKO). Proteins capable 
of binding IgE were detected using chemiluminescence (ECL, 
GE Healthcare). Several different reactive bands capable of 
binding IgE from the patient’s serum are apparent. The bands 
binding IgE most strongly correspond to molecular weights 
of approximately 18, 25, and 50 kDa (Lane 1).
Inhibition of IgE with the glycoprotein bromelain (Figure, 
Lane 2) shows the same pattern as no inhibition (Figure, 
Lane 1), suggesting that the boxwood protein bands binding the 
patient’s IgE contain no MUXF3 carbohydrate determinants 
(MUXF3 is the sugar found in bromelain).
Wood allergy is a relatively common condition, especially 
as an occupational disease. In the case of boxwood, however, 
despite its widespread use in our setting, we were only able 
to find 1 article on contact dermatitis [5]. To our knowledge, 
no data have been reported on the underlying immunological 
mechanism associated with exposure to boxwood. 
We report the case of an atopic patient whose hobby 
involved working with boxwood. His symptoms (first nasal and 
conjunctival, then bronchial) developed 2 years after he began 
working with the wood. He did not report contact urticaria or 
dermatitis and is currently unaffected by either.
The patient reported no symptoms on exposure to other 
woods, and skin tests with commercial extracts of various 
woods proved negative. Boxwood allergy was confirmed 
based on the patient’s medical history, the skin test result with 
boxwood extract, and IgE-immunodetection, which revealed 
specific IgE against components of the boxwood extract in 
the patient’s serum. The bands binding most strongly to IgE 
had molecular weights of approximately 18, 25, and 50 kDa.
The specialist literature contains case reports demonstrating 
cross-reactivity between latex and wood [6-7]. In the case we 
report, the presence of IgE against whole latex extract but 
not against single latex allergens might be explained by the 
combination of cross-reactive carbohydrate determinants (CCD) 
and alcohol consumption, as demonstrated in other studies [8-9].
A high prevalence of IgE against CCDs has been described 
in wood-sensitized workers [10]. As the patient had IgE 
against MUXF3 (a fairly ubiquitous CCD that can be found 
in the glycoprotein bromelain), the IgE-immunodetection 
result could have been attributable to carbohydrate cross-
reactivity. To rule out this possibility, the patient’s serum was 
preincubated with bromelain before IgE-immunodetection 
was carried out with the nitrocellulose strip containing 
boxwood extract. Since bromelain did not inhibit IgE binding 
to boxwood proteins, we can conclude that this was a case of 
primary sensitization to boxwood proteins rather than CCD 
cross-reactivity.
In conclusion, boxwood allergy should be taken into 
account when investigating the cause of allergy in patients 
exposed to this wood at work or because of a hobby.
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Figure. IgE immunodetection with boxwood extract. The protein 
components in the boxwood extract were separated by SDS-PAGE. Lane 1, 
patient’s serum; Lane 2, patient’s serum preincubated with bromelain. 
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Ranitidine is a commonly prescribed H2-receptor (H2R) 
antagonist mainly used for the prevention and treatment of 
gastroesophageal diseases caused or aggravated by gastric 
acid. Reports of immediate hypersensitivity reactions to the 
drug are scarce [1,2]. We report a case of anaphylaxis to 
intravenous ranitidine administration. 
A 16-year-old girl was admitted to the hospital for 
surgical repair of an anterior cruciate ligament injury. During 
induction of general anesthesia, she developed anaphylactic 
shock with marked hypotension, bronchoconstriction, and 
facial angioedema. After intensive treatment with repeated 
administration of adrenaline and excessive fluid replacement, 
the patient’s vital signs stabilized and she was transferred to 
the intensive care unit for 48 hours. 
Upon discharge the patient was referred to the “D. 
Kalogeromitros” Allergy Unit for allergological investigation. 
The detailed personal and family medical history revealed 
no atopy, previous surgery, or drug allergies. All the drugs 
received preoperatively and intraoperatively were classified 
into 3 categories for testing: β-lactams (cefoxitin), general 
anesthetics (propofol, midazolam, cis-atracurium), and 
others (ranitidine, ondansetron, and metoclopramide). Both 
in vitro (ImmunoCap, ThermoFisher Scientific) and in vivo 
tests (skin prick tests [SPTs], and intradermal [ID] tests) to 
β-lactams were negative. Skin tests to general anesthetics, 
latex, ondansetron, and metoclopramide were also negative. 
By contrast, ranitidine (Lumaren 25mg/mL, Elpen) yielded 
positive SPT (full strength) and ID (1/1,000 and 1/100 
dilutions) results. SPT and ID tests to pure ranitidine (Sigma-
Aldrich Co) at the same concentrations were also positive. 
The 1/10 ranitidine dilution was not tested as it produced an 
irritant reaction in 4 out of 5 unexposed individuals. Possible 
cross-reactivity between H2R antagonists was evaluated with 
SPT and ID tests of nonirritant preparations of cimetidine 
(Tagamet 200 mg/2mL, Vianex) and famotidine (Peptan 
20 mg, Vianex). The results were all negative. Neither the 
patient nor her parents recalled previous ranitidine intake, 
although this possibility cannot be completely ruled out.
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 After obtaining written informed consent and ensuring 
that resuscitation equipment was readily available, we 
performed a challenge with intravenous cefoxitin; there 
were no adverse reactions. Due to a lack of standardization 
of skin tests to ranitidine and the rare occurrence of allergic 
reactions to H2R antagonists, we decided to perform a single-
blind, placebo-controlled, graded oral challenge to ranitidine 
hydrochloride (Zantac tablet 150 mg, GlaxoSmithKline), 
with both the parents’ and the patient’s full consent. The 
challenge was performed in a tertiary hospital under the 
care of highly trained and experienced staff. Ranitidine was 
administered in 6 steps, starting from 0.15 mg (1:1000 of a 
full dose) up to a single dose of 150 mg. Almost 60 minutes 
after the final step, the patient developed moderate urticarial 
lesions on the abdomen accompanied by shivering and a vague 
sense of weakness. Serum tryptase levels, measured before the 
challenge and at 30 and 150 minutes after the reaction, showed 
no significant changes (4.0, 3.9, and 4.53 μg/mL respectively; 
normal values, <11.4 μg/mL). The mildness of the reaction 
after a full dose of ranitidine was inconsistent with the acute 
onset and severe reaction of the reported episode. Therefore, a 
second, this time intravenous, graded challenge was agreed on 
and scheduled for a week later. The patient was challenged with 
injectable ranitidine hydrochloride (Zantac injectable solution 
25 mg/mL, GlaxoSmithKline) with an even lower starting dose 
of 1/10 000 the therapeutic dose (0.005 mg) and 30-minute 
between-dose intervals. Five minutes after receiving the sixth 
dose (25 mg), the patient developed diffuse urticaria, back pain, 
headache, and tachycardia. Antihistamines and corticosteroids 
were administered and the symptoms fully remitted within 
60 minutes. The challenge was considered positive and was 
therefore interrupted. Serum tryptase levels were increased 
30 and 150 minutes after the onset of the reaction (7 and 
6.8 μg/mL respectively). Possible cross-reactivity with other 
H2R antagonists was assessed by open challenges with oral 
famotidine (Peptan tablet 20 mg, Vianex) and injectable 
cimetidine (Tagamet injectable solution 200 mg/2 mL, 
Vianex). The results were negative in both cases.
Histamine levels in both serum and whole peripheral 
blood were determined fluorometrically in duplicate before 
each challenge, 30 minutes after the reaction to intravenously 
administered ranitidine, and upon completion of the uneventful 
oral challenge with cimetidine [3]. Serum histamine levels 
were increased—from 4.3 ng/mL to 17.1 ng/mL—after the 
positive challenge with ranitidine, but they remained low after 
the negative challenge with cimetidine (Table). Interestingly, 
the patient’s baseline whole blood histamine levels were 
higher than those in 5 healthy volunteers (mean  [SD] level 
of 18.6 [7.2] ng/mL). By contrast, baseline serum histamine 
levels in the symptom-free period were comparable to those of 
the volunteers (mean [SD] level of 8.5 [2.0] ng/mL). Moreover, 
increased monocytes were observed in the patient’s baseline 
blood cell count (15.1% vs normal values of 2%-10%), 
although post-challenge measurements were not performed. 
The high baseline histamine levels in the patient’s whole blood 
but not in serum were attributed to the increased histamine 
content of the blood cell fraction, which, together with 
the increased blood monocyte counts and increased serum 
histamine levels after the challenge with ranitidine, provides a 
rationale for the future investigation of monocyte involvement 
in responses such as the one in our patient [4]. 
Since reports of ranitidine-induced immediate 
hypersensitivity reactions are increasing in the literature [5,6], 
further elucidation of the underlying mechanism is important. 
Although the specificity and sensitivity of skin tests in 
diagnosing ranitidine-induced anaphylaxis have not been 
fully established, the high frequency of positive results and 
the reports of serum specific IgE detection indicate an IgE-
mediated mechanism [1,7]. 
So far, only a few cases of cross-reactivity between H2R 
antagonists have been demonstrated by skin testing [5,8], 
and just 1 case has been confirmed by challenge testing, the 
gold standard of clinical diagnosis [5]. Failure to demonstrate 
cross-reactivity with other H2R antagonists may be due to 
ligand-specific signaling [9]. Skin testing followed by carefully 
monitored challenges to alternatives is recommended if an H2R 
antagonist suspected of triggering a hypersensitivity reaction 
must be substituted by another member of the same family [10]. 
Cimetidine would be the safest alternative in such a case [8]. 
Considering the recent concept of the immunomodulatory 
role of histamine [4], the potential contribution of a tentative 
histamine-related etiological mechanism mediating selective 
hypersensitivity to ranitidine highlights the need for further 
investigation. New knowledge on the hitherto poorly defined 
mechanisms underlying drug hypersensitivity reactions 
will eventually lead to valuable diagnostic, prognostic, and 
therapeutic tools.
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In recent decades, several authors have described their 
experience with oral immunotherapy (OIT) in children allergic 
to cow’s milk (CM) [1-2]. Although allergic reactions during 
OIT are frequent, few cases of late complications due to these 
innovative therapeutic procedures have been reported [3].
We report the case of a 14-year-old boy allergic to CM 
protein. When the boy was 10 years old, skin prick tests (SPTs) 
with commercial extracts (ALK-Abelló) produced a wheal 
measuring 10x4 mm for CM, 18x15 mm for α-lactalbumin, 
15x10 mm for β-lactoglobulin, and 7x4 mm for casein 
(histamine, 4x4 mm). Milk and casein specific IgE (sIgE) 
levels (Phadia InmunoCAP) were 15 kU/L and 11.1 kU/L, 
respectively, and the peripheral blood eosinophil count was 
700 cells/µL. At the time, the patient underwent an OIT 
protocol with CM. After an induction phase of 9 weeks, he 
achieved tolerance to a dose of 250 mL of milk taken once a 
day. One year later, the patient had to reduce milk intake to 
125 cc a day and finally to 75 cc due to poor tolerance with 
higher doses (oral itching, nausea, and epigastric pain).
At the age of 13 years, 25 months after achieving 
tolerance to the maximum dose, the patient began with 
food impaction, dysphagia, and choking episodes once or 
twice a week, which were resolved by drinking liquids. 
Taking into account these symptoms and the history of 
the patient, proton-pump inhibitor (PPI) treatment was 
prescribed at a dose of 40 mg per day. The patient became 
asymptomatic 2 months after starting this treatment. At this 
time, the first endoscopy was performed, showing linear 
furrows in distal and medial esophageal mucosa and 30 
eosinophils per high-power field (hpf) in the proximal and 
distal esophagus. Since these findings fulfilled the 2011 
consensus criteria for eosinophilic esophagitis (EoE), oral 
fluticasone (400 mcg/24 h) was added to the PPIs, and CM 
was excluded from the diet [4]. Nevertheless, the patient 
continued to consume small amounts of CM, present in 
other food. In the following 2 months, he had 2 episodes 
of facial erythema and itching, and an anaphylactic episode 
after consuming small amounts of CM hidden in several 
dishes in a restaurant (omelette, sandwich with mayonnaise, 
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fried squid, rice, and fish). The presence of milk in the food 
consumed was confirmed by the chef.
The study performed at this time included a positive SPT 
to CM (wheal, 5x5 mm) and a negative SPT to fish, seafood, 
eggs, legumes, nuts, and anisakis. Milk and casein sIgE levels 
showed figures of 12.6 kU/L and 10.7 kU/L, respectively. SIgE 
was negative to rice, squid, and anisakis. Oral challenges with 
eggs, rice, and cephalopods were negative. Peripheral blood 
eosinophils were 600 cells/µL and serum tryptase levels were 
normal.
Given these results, we suspected that the reactions 
were caused by traces of CM. A strict milk avoidance diet 
was indicated and oral fluticasone was withdrawn but PPIs 
maintained.
A second endoscopy was performed 2 months after strict 
milk avoidance. Macroscopically, the esophageal mucosa was 
normal, and proximal and distal mucosal biopsies revealed 
10-12 eosinophils/hpf. Since the number of eosinophils in the 
esophageal tract had been reduced, we decided to maintain 
treatment with PPIs and to perform a repeat endoscopy 5 
months later. 
A third endoscopy showed a normal esophageal mucosa 
with no eosinophils in the biopsy samples. Peripheral blood 
eosinophils showed similar figures throughout the process. 
PPI treatment was discontinued and the patient is still 
asymptomatic, a year later.
We have reported the case of a teenage patient allergic 
to CM who achieved tolerance of milk with an OIT protocol 
but developed EoE after 2 years of a maintenance phase with 
regular milk intake. This is the second case of eosinophilic 
esophagitis in 25 patients who have undergone OIT so far in 
our allergy department. The course was similar in both patients, 
with partial loss of tolerance after starting the maintenance 
phase, possibly suggesting that this late complication is more 
common in patients with worse outcomes after OIT.
The patient presented with typical symptoms seen in 
teenagers with EoE (dysphagia and choking) and the diagnosis 
was confirmed by endoscopy and esophageal tract biopsies. 
In compliance with guidelines on EoE management, PPI 
treatment was started 2 months before the first endoscopy to 
exclude gastroesophageal reflux disease and/or PPI-responsive 
esophageal eosinophilia [4-6]. Due to the favorable clinical 
course and the persistent histological remission after exclusion 
of CM from the diet, we suspected that CM proteins might 
be responsible for the EoE [7]. Tolerance to milk disappeared 
in a few weeks after exclusion of regular milk intake and the 
patient developed anaphylaxis following the ingestion of small 
amounts of milk hidden in other foods.
Recently, Sánchez García et al [8] reported on 3 patients 
with CM protein allergy treated with OIT who developed 
typical symptoms of EoE between 3 and 14 months after 
achieving tolerance of a dose of 200 mL of milk taken once 
a day. EoE was confirmed by esophageal biopsies and the 
clinical picture resolved after CM avoidance. Ridolo et al [9] 
described the case of an 11-year-old boy who developed EoE 
after OIT for egg allergy and achieved histologic remission 
after egg withdrawal. Hofmann et al [10], in turn, reported on 
a patient who developed EoE while being treated with OIT for 
peanut allergy. The EoE resolved after a peanut-free diet. Our 
case is similar to previous reports, except that EoE developed 
somewhat later (>2 years after completion of the protocol). 
What is also particularly striking in our patient is the rapid 
loss of CM tolerance after elimination of regular milk intake.
We conclude that EoE is a possible late complication in 
food-allergic patients treated with OIT. It is important that 
both patients and doctors are aware of this possibility and 
that patients are monitored long term. A strict elimination diet 
with the implicated food should be prescribed to resolve the 
EoE and avoid the risk of severe reactions due to the possible 
disappearance of tolerance after eliminating regular intake of 
the offending food. 
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Hospital Sant Joan de Déu in Manresa forms part of the 
Althaia Foundation healthcare network and provides allergy 
care service for central Catalonia. Population growth due in 
part to immigration and increased life expectancy, together 
with an increased prevalence of allergic diseases, has 
contributed to longer waiting lists at our allergy department 
in recent years. The aim of this paper was to analyze whether 
the increase in demand for care over a 5-year study period 
affected the reasons for allergy consultations. The study 
forms part of the department’s strategic plan (SP) for 2005-
2010 [1].
We analyzed and compared waiting lists for first allergy 
consultation visits and specific reasons for consultation in 
2005 and 2010. Patients were divided into 4 groups according 
to their presenting complaint: 1) respiratory allergy (rhinitis 
and/or bronchial asthma), 2) food allergy, 3) drug allergy, 
and 4) skin allergy (urticaria, angioedema, atopic or contact 
dermatitis). Data were obtained from allergy department 
records and information provided by the Althaia Foundation’s 
department of management and biological diagnosis. 
Population data were extracted from the IDESCAT census 
database of the Catalan Government.
According to official census data, in 2005 the population in 
the area served by the allergy department consisted of 238 486 
inhabitants. The average waiting time for a first appointment 
was 10 months (300 days). There were 1519 first allergy 
visits in 2005. Broken down by groups, there were 881 visits 
in Group 1 (respiratory allergy), 379 visits in Group 2 (food 
allergy), 212 visits in Group 3 (drug allergy), and 273 visits 
in Group 4 (skin allergy).
In 2010, the population in the same area was 259 079 
inhabitants (an increase of 20 593 people). However, the 2010 
reference area also included the areas originally covered by 
Hospital d’Igualada (111 000 inhabitants) and Hospital Nostra 
Senyora de Meritxell de Andorra (84 082 people); these areas 
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are now covered by our allergy department through strategic 
partnerships defined in the SP. Thus, the total population 
attended was about 453 161 people. The overall waiting period 
for a first appointment was 4.5 months (165 days). There were 
3018 first consultations: 1962 for respiratory allergy, 905 for 
food allergy, 482 for drug allergy, and 513 for skin allergy.
The mean number of specific IgE determinations requested 
per patient was 3.4 in 2005 compared with 4.27 in 2010.
The prevalence of allergic diseases has increased in recent 
years and with it the number of allergy consultations [2]. 
According to IDESCAT, there was a 7.95% increase (20 593 
inhabitants) in the population of central Catalonia between 
2005 and 2010 [3]. This was due in part to a rise in the 
immigrant population, which currently represents 13.27% 
of the census population (9.23% in 2005). Apart from this 
population increase, in 2009 our allergy department also 
started to provide care, for the reference populations originally 
covered by Hospital d’Igualada and Hospital Nostra Senyora 
de Meritxell d'Andorra
The increased activity did not reflect a significant change 
in reasons for allergy consultations. There was a slight increase 
in the percentage of food allergy studies (from 21.72% in 
2005 to 23.43% in 2010), possibly due to the increased 
number of pollen-polysensitized individuals in our area, who 
also have plant food allergies. A study with longer and more 
detailed follow-up of these patients would be necessary. The 
Alergológica 2005 study (a national clinical and epidemiologic 
project that described the profile of patients treated in a Spanish 
sample of allergology departments) also showed a slight 
increase in consultations for food allergy with respect to data 
from the same study in 1992 [4]. 
There was a slight reduction in the number of drug allergy 
consultations (15.64% in 2005 vs 13.28% in 2010), most 
probably due to improvements in the patient referral process.
We did not detect a significant increase in the percentage 
of respiratory allergy consultations, although the number of 
patients sensitized to at least 1 allergen was probably higher in 
2010 than in 2005. The number of specific IgE determinations 
per patient rose from 3.4 in 2005 to 4.27 in 2010, primarily 
due to an increase in the number of patients presenting specific 
IgE antibodies to aeroallergens. In other words, even though 
there was not a significant increase in the percentage of patients 
with rhinitis and asthma in 2010, improvements in patient 
screening probably led to a greater number of positive tests. 
The application of referral criteria as part of the department’s 
SP improved the quality of first consultations, which probably 
influenced the higher percentage of positive test results in 
2010 [5]. According to the Alergológica 2005 study, there was 
a reduction in the number of consultations for bronchial asthma 
and a stable rate for rhinitis in the period 1992-2005 [4]; these 
observations are consistent with our findings. The division of 
patients into groups based on the reason for allergy consultation 
may have biased our results since patients may consult for 
multiple reasons [6,7].
In conclusion, the increased demand for allergy testing 
has not led to a significant change in reasons for consultation. 
There was a slight increase in consultations for food allergy 
and probably a greater number of patients with positive tests, 
although this needs to be analyzed in more detail.
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Heparins are widely used for treatment and prophylaxis 
of thromboembolic disorders. They comprise a spectrum 
of agents, including unfractionated heparin (UFH), low-
molecular-weight heparins (LMWHs), heparinoids, and 
pentasaccharides. The most common hypersensitivity reactions 
to heparins are delayed-type erythematous plaques that occur 
after subcutaneous application [1]. Immediate-type reactions to 
heparin compounds, which probably involve an IgE-mediated 
pathomechanism, seem to be uncommon and very few cases 
have been published [2-6].
A 33-year-old man was referred to our allergy unit 
with a suspected drug allergy. Six months earlier, he had 
undergone tibial surgery and 3 days after the procedure he 
developed generalized urticaria and facial edema. He was 
receiving ibuprofen and subcutaneous bemiparin. Ibuprofen 
was stopped and antihistamines were prescribed, but the 
urticaria reappeared each morning 15 to 20 minutes after 
bemiparin administration for 2 weeks. Bemiparin was therefore 
changed to another LMWH, enoxaparin. A few minutes after 
receiving the first dose of subcutaneous enoxaparin, the patient 
developed hypotension, tachycardia, dyspnea, and worsening 
of urticaria that required treatment in the emergency room. 
Enoxaparin treatment was stopped and the urticaria resolved 
in less than 24 hours.
The patient had a previous history of mild rhinitis and 
sensitization to Chenopodiaceae plants. Skin prick tests (SPTs) 
and intracutaneous tests (ICTs) with UFH and various types 
of LMWHs (enoxaparin, bemiparin, dalteparin, nadroparin, 
tinzaparin), fondaparinux, and lepirudin (hirudin) were 
performed as previous described [1-2]. 
The SPTs were negative for all the compounds tested. The 
ICTs (1/100 dilution) were positive for all the LMWHs and 
negative for fondaparinux and lepirudin. The ICT with UFH 
was also negative (up to a 1/10 dilution).
A basophil activation test was performed with the 
BASOTEST kit (Orpegen). After in vitro allergen-specific 
stimulation, activated basophils express CD63, which can 
be detected using monoclonal antibodies anti-CD63-FITC 
and anti IgE-PE. Enoxaparin, bemiparin, dalteparin, UFH, 
fondaparinux, and lepirudin were used at 2 dilutions (1/40 
and 1/160) and the percentage of basophils expressing CD63 
was measured using a FACSCanto flow cytometer (Becton 
Dickinson).
The BASOTEST was positive for enoxaparin, bemiparin, 
dalteparin, and UFH and negative for fondaparinux and 
lepirudin [Figure]. 
To identify an alternative drug and after obtaining informed 
consent, we performed a provocation test with fondaparinux 
and lepirudin, both of which were tolerated. Because of the 
discordance between the skin test results and the BASOTEST 
results for UFH, we also performed a provocation test with 
intravenous UFH under careful supervision. The drug was 
tolerated well at full doses.
Although heparins are commonly used drugs, allergic 
reactions are rare. The most common reactions involve 
cell-mediated hypersensitivity with clinical manifestations 
of erythematous plaques and sometimes maculopapular 
exanthemas [1]. Immediate-type hypersensitivity reports are 
extremely rare [2-6] and not all describe an allergy study. 
Moreover, diagnosis is sometimes challenging, as patients 
may be taking concomitant medication. This was the case 
with our patient, in whom nonsteroidal anti-inflammatory drug 
intolerance was initially suspected.
In our patient, the immediate onset of cutaneous symptoms 
after administration of bemiparin and of anaphylaxis after 
enoxaparin administration, together with the positive skin test 
and BASOTEST results, strongly suggested an IgE-mediated 
reaction to these compounds.
Although the sensitivity and specificity of skin tests 
have yet to be determined in immediate-type reactions to 
heparins, our case supports previous findings that suggest that 
intradermal testing with diluted drugs may be a useful tool in 
the diagnosis of these reactions [1-3].
We found that the BASOTEST was positive to all LMW 
heparins tested. Caballero et al [7] also reported on 2 patients 
with heparin-induced acute urticaria in which the BASOTEST 
had a good correlation with clinical findings, and suggested 
using this in vitro diagnostic technique to study possible 
sensitization to heparins to avoid the risks associated with 
challenge tests. 
Figure. Flow cytometric analysis of activated basophils. Activated 
basophils are expressed as the percentage of CD63+ cells in the upper 
right quadrant. Plots correspond to the percentage of activated basophils 
after incubation with buffer alone (negative control), anti-IgE (positive 
control), and 1/40 dilution of different heparins.
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In our patient, the BASOTEST was strongly positive for 
UFH, even though the patient tolerated the administration of 
the drug. One possible explanation for this discordance may 
be depolymerization of UFH, with generation of low LMWH 
during the incubation of basophils in the BASOTEST.
The pattern of cross-reactivity between the different 
heparins has not been well established. Cross-reactivity may be 
extensive in cell-mediated reactions to UFH and LMWH [8-10]. 
Information regarding immediate reactions is sparser. Harr 
et al [2] described a patient with immediate sensitization to 
dalteparin with extensive cross-reactivity to other LMWHs 
and to the glycosaminoglycan danaparoid. The patient, 
however, tolerated UFH, the pentasaccharide fondaparinux, 
and lepirudin (hirudin). Other authors have reported cross-
reactivity between UFH and LMWH [3,6]. 
Our patient showed cross-sensitization between all 
the LMWHs tested, but he tolerated UFH, fondaparinux, 
and lepirudin. Perhaps different cross-reactive patterns are 
possible, as documented in previously reported cases of 
anaphylaxis to anticoagulants [2,3]. 
In some patients sensitized to heparins, fondaparinux 
seems to be an alternative due to its lower allergic potential 
and lack of cross-reactivity, probably because of its full 
synthetic structure, ultra-low molecular weight, and different 
allergenic epitope [10]. Nevertheless, an allergy study should 
be performed before administration. Hirudins may be another 
alternative.
In conclusion, skin tests and the BASOTEST may help 
to study immediate sensitization to heparins, determine 
cross-reactivity between the different compounds, and most 
importantly, find a safe alternative for patients sensitized to 
heparins. 
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Matricaria chamomilla, Compositae (German chamomile), 
has traditionally been used for medicinal purposess for its 
antioxidant, antimicrobial, and anti-inflammatory properties, 
as well as for its antispasmodic and anxiolytic effects [1]. 
Chamomile has been described as an elicitor of type-IV 
delayed and anaphylactic reactions after ingestion of tea [2-6]. 
There have been reports of occupational asthma and rhinitis 
caused by inhalation exposure to chamomile dust, but they do 
not specify whether or not those affected tolerated drinking 
chamomile tea [7,8]. We describe a case of occupational 
allergic rhinoconjunctivitis induced by M chamomilla in a 
patient who tolerated ingestion of chamomile tea. 
A 47-year-old woman in charge of packing herbal teas at a 
herbalist’s for 10 years reported episodes of intense rhinorrhea, 
sneezing, nasal and ocular itching, conjunctival erythema, and 
watery eyes for 3 years. The symptoms disappeared during 
weekends and holidays, suggesting occupational exposure. 
So far the patient has tolerated ingestion of chamomile and 
peppermint tea.
The patient had a normal respiratory function test, with a 
forced expiratory volume in the first second (FEV1) of 120%. 
The bronchodilator test was negative. 
Skin prick tests (Bial-Aristegui) and ImmunoCAP 
(Phadia) were positive for chamomile pollen (M chamomilla) 
(16.4 kU/L), peppermint (Mentha piperita) (0.59 kU/L), fennel 
(Foeniculum vulgare) (0.50 kU/L), and tea plant (Camellia 
sinensis) (0.24 kU/L); pollen mixtures of weed (wheal, 
22x21 mm), grasses (6x14 mm) and trees (10x12 mm); and 
Artemisia species (20x21 mm, 7.47 kU/L), Aster species 
(15x10 mm), rue (Solidago virgaurea) (12x9 mm, 2.65 kU/L), 
grama (Cynodon dactylon) (0.53 kU/L), and ryegrass (Lolium 
perenne) (0.5 kU/L). The diameter of wheals corresponding to 
controls were 5 mm for histamine and 0 mm for glycerol saline. 
Prick-to-prick tests performed with extracts from herbs 
handled by the patient were positive for chamomile (22x21 mm), 
peppermint (10x16 mm), and fennel (4x6 mm). Nasal provocation 
tests were performed with chamomile and peppermint extracts. 
The patient showed an immediate response consisting of 
hydrorrhea, sneezing fits, and a 60% decrease in peak nasal 
inspiratory flow (PNIF), with 1:1000 wt/vol chamomile extract. 
Crushed dried chamomile flowers handled by the patient 
(10 g) were extracted with phosphate buffered saline (PBS) 
(350 mL) (4°C/72 h). After centrifugation (4500 g/30 min) 
the supernatant was freeze-dried and the pellet was recovered 
or defatted with acetone (1:10 wt/vol, 4°C/1 h) followed by 
acetone/methanol (8:1 vol/vol, 4ºC/1 h), and extracted with 
PBS (4°C/2 h). After centrifugation, the supernatant was 
dialyzed and freeze-dried. 
The extracts (15 μg) were analyzed by SDS-PAGE and electro-
transferred onto a polyvinylidene difluoride membrane (Sequiblot, 
Bio-Rad) for IgE immunoblotting with the patient’s serum. 
SDS-PAGE revealed no recognizable protein bands, but a 
diffuse smear in all extracts (Figure A). IgE immunoblotting 
showed that the patient’s serum detected allergens from 175 
to 25 kDa in the 3 extracts (Figure B). 
Digestion of the chamomile extracts with simulated gastric 
fluid (12.8 μg/μL pepsin A [Sigma] in 50 mM HCl, 37ºC/30 
min) eliminated the detection (Figure 1C), possibly explaining 
why the patient tolerated the ingestion of chamomile tea. 
Allergen Mat c 1 (17 kDa) is the only allergen described 
in chamomile (www.allergome.org). Furthermore, a smear of 
50 to 23 kDa has been reported [5]. These IgE detections were 
found in cases of anaphylaxis after ingestion of chamomile 
tea, so the allergens should be pepsin-resistant, although this 
experiment was not performed.
The case reported here is the first to describe occupational 
allergic rhinoconjunctivitis induced by inhalation of 
chamomile dried flowers in a patient who tolerated ingestion 
of chamomile tea. 
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Figure. Analysis of extracts prepared with chamomile flowers handled 
by the patient. A, SDS-PAGE and Coomassie staining. Lanes: (1) 
supernatant obtained after phosphate buffered saline (PBS) extraction; 
(2) pellet obtained after PBS extraction; and (3), defatted extract. B, IgE 
immunoblotting performed with the patient’s serum. C, Performed after 
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